SNZZF Stock Chart & Stats
$0.39
$0.00(0.00%)
At close: 4:00 PM EDT
$0.39
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.29 - $0.75
Previous CloseN/A
Volume25.00K
Average Volume (3M)14.54K
Market Cap
$52.06M
Enterprise Value$665.00
Total Cash (Recent Filing)$37.11M
Total Debt (Recent Filing)$21.37M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding157,215,040
10 Day Avg. Volume40,131
30 Day Avg. Volume14,538
Financial Highlights & Ratios
PEG Ratio1.41
Price to Book (P/B)2.61
Price to Sales (P/S)7.63
P/FCF Ratio-7.10
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$15.82M
Bulls Say, Bears Say
Bulls Say
Commercialization ScaleRevenue scaling from 2021–2025 and a TTM level near 103M indicate meaningful commercialization progress. A larger revenue base can support broader clinical adoption and improve operating leverage if the company converts this scale into sustainable margins over coming quarters.
Improving Gross MarginThe improvement in gross margin suggests product economics have strengthened as the business has scaled. If maintained, higher gross profitability can provide more resources to fund commercial expansion and gradually narrow operating losses without requiring equivalent revenue growth.
Low Financial LeverageVery low leverage limits near-term solvency pressure and reduces the burden of interest payments on a loss-making business. This provides greater financial flexibility to invest in commercialization and manage operating volatility, although it does not remove the need to address cash consumption.
Bears Say
Severe UnprofitabilityDeeply negative net and operating margins show that current revenue is far from covering the company’s cost base. Persistent losses weaken internal funding capacity and make progress toward breakeven dependent on substantial margin improvement or continued external financing.
Persistent Cash BurnSustained negative operating and free cash flow indicates that the business is not yet self-funding its operations. Continued cash burn can require additional financing and constrain investment choices, while also increasing dilution or funding risk if losses persist.
Recent Revenue Momentum WeaknessA sharp reversal in TTM revenue growth is a meaningful challenge because the company must expand revenue to absorb its current cost base. If weaker momentum continues, commercialization progress may not translate into operating leverage, delaying a credible path toward profitability.
Senzime AB News
SNZZF FAQ
What was Senzime AB’s price range in the past 12 months?
Senzime AB lowest stock price was $0.29 and its highest was $0.75 in the past 12 months.
What is Senzime AB’s market cap?
Senzime AB’s market cap is $52.06M.
When is Senzime AB’s upcoming earnings report date?
Senzime AB’s upcoming earnings report date is Oct 29, 2026 which is in 43 days.
How were Senzime AB’s earnings last quarter?
Senzime AB released its earnings results on Jul 16, 2026. The company reported -$0.014 earnings per share for the quarter.
Is Senzime AB overvalued?
According to Wall Street analysts Senzime AB’s price is currently Overvalued.
Does Senzime AB pay dividends?
Senzime AB does not currently pay dividends.
What is Senzime AB’s EPS estimate?
Senzime AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Senzime AB have?
Senzime AB has 157,215,040 shares outstanding.
What happened to Senzime AB’s price movement after its last earnings report?
Senzime AB reported an EPS of -$0.014 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Senzime AB?
Currently, no hedge funds are holding shares in SNZZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Senzime AB
Senzime AB (publ) is a medical technology firm specializing in the creation and distribution of advanced patient monitoring solutions. These systems are designed to oversee patients undergoing anesthesia across various global markets, including Europe, Oceania, Asia, Canada, and the United States. Among its primary offerings is the TetraGraph, a sophisticated monitor designed to assess and display muscle function in surgical patients administered neuromuscular blocking agents, by stimulating, measuring, and analyzing responses. This system is complemented by the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. For data management, TetraConnect serves as a portal, allowing clinicians to conveniently access, view, and export TetraGraph data records in PDF or Excel formats. Furthermore, TetraGraph Device Connectivity facilitates the transfer of data from the TetraGraph Monitor to other patient monitoring systems, while the TetraGraph Philips Interface specifically enables the transmission of critical neuromuscular monitoring parameters—such as TOFC, TOFR, PTC, and TOF bars—to Philips patient monitors, with readings visible on the Philips Intellivue Monitor. Senzime is also actively developing the CliniSenz Analyzer, intended for continuous postoperative patient monitoring within hospital settings. Another innovation in its pipeline is the Onzurf Probe, a sterile, CE-marked single-use device leveraging micro-dialysis technology for continuous sampling from gastrointestinal organs, including the esophagus, stomach, and liver. The company maintains a strategic licensing and connectivity partnership with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to integrate seamlessly with Masimo's Root monitoring system and their digital hubs, thereby enabling interaction with hospital clinical information systems and electronic health records. Established in 1999, Senzime AB (publ) operates from its headquarters in Uppsala, Sweden.
Technical Analysis
Paxman AB
―
SciBase Holding AB
―
Bactiguard Holding AB
―
Acarix AB
―
Sedana Medical AB
―
Ownership Overview
―
Insiders
― Other Institutional Investors
99.97% Public Companies and
Individual Investors